The development of pre-clinical models to study and identify novel biomarkers in muscle invasive bladder cancer
Bladder cancer is the 4th commonest malignancy in the United Kingdom and worldwide there are nearly 400,000 new cases every year with over 150,000 deaths. The gold standard treatment for muscle invasive bladder cancer is radical cystectomy with neoadjuvant chemotherapy. Despite this the overall surv...
Main Author: | Douglas, James William Robert |
---|---|
Other Authors: | Crabb, Simon ; Packham, Graham |
Published: |
University of Southampton
2015
|
Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.729610 |
Similar Items
-
Biomarkers for Predicting Clinical Outcomes of Chemoradiation-Based Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer
by: Fumitaka Koga, et al.
Published: (2018-09-01) -
Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
by: Xiangming Cheng, et al.
Published: (2018-11-01) -
Novel treatments in muscle invasive bladder cancer
by: Maddineni, Satish B.
Published: (2008) -
Integrative multi-omics analysis of muscle-invasive bladder cancer identifies prognostic biomarkers for frontline chemotherapy and immunotherapy
by: Qianxing Mo, et al.
Published: (2020-12-01) -
Biomarkers for non-muscle invasive bladder cancer: Current tests and future promise
by: Fadi Darwiche, et al.
Published: (2015-01-01)